Active Pharmaceutical Ingredient

Isodiol Receives Government Approval for Pure, Natural CBD as an Active Pharmaceutical Ingredient

Isodiol’s subsidiary, BSPG Laboratories, LTD. has commercialized manufacturing of pure, natural CBD as an API for the pharmaceutical and research industry.

April 26, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical actives and health and wellness products, is pleased to announce that the Company’s wholly owned subsidiary BSPG Laboratories, LTD. has received government approval from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of the active substance Cannabidiol (CBD) under certificate number:  UK API 48727.

MHRA is an executive agency of the United Kingdom’s Department of Health and is the regulatory agency that regulates medicines and medical devices. The MHRA is also a part of the European system of approval, where the MHRA or other national bodies can take on the verification work on behalf of all its members.  Further, the MHRA is recognised globally as an authority in its field and plays a leading role in protecting and improving public health and supports innovation through scientific research and development.

“This approval validates the consistent quality of our pure, natural CBD isolate and the patented manufacturing processes,” said CEO of Isodiol, Marcos Agramont.  “This event is a first in the industry and now enables Isodiol to focus on the development of CBD based drugs that will address a myriad of conditions that are affecting so many people around the world.  With this approval, we will now rapidly advance our pharmaceutical and drug development divisions.”

With the MHRA approval and because it meets all legal requirements under international law, the Company is now able to export the pure, natural CBD anywhere in the world, subject to pharmaceutical regulations.  This approval sets Isodiol apart from all other CBD companies globally as a secure and reliable supplier positioned to be able to serve this newly created demand for CBD drug development, approved pharmaceutical applications, research, clinical studies, and clinical trials.  Upon completion of the company’s new state-of-the-art manufacturing facility in Q1-2019, the Company’s production output capabilities will increase to approximately 20,000 kilos of CBD – API quality input material annually.

Dean Billington, QP Consultant of BSPG Laboratories LTD stated, “This is a huge achievement by BSPG laboratories and reflects the significant work and efforts made by the staff and management. The API registration also clearly demonstrates the commitment of BSPG Laboratories and Isodiol to manufacture the highest quality CBD currently available worldwide.”

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.


“Marcos Agramont” CEO & Director


[email protected]

BeTru Wellness
C3 Global Biosciences

Join Us On Facebook:
Twitter: @isodiol

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.